

Special Issue

Novel Therapeutic and Preventive Approaches for Cancer

Message from the Guest Editors

Tremendous advancements have been made to effectively combat various malignant diseases in the past few decades. Early detection and monitoring with a battery of biomarkers and targeted therapy with various molecular inhibitors are emerging continuously to increase our strength to continue our fight against cancer. On the other hand, various preventive measures such as HPV vaccination and mammographic imprinting have remarkably improved our ability to prevent or detect cancer early. Various mitochondria- and exosome-based therapeutic approaches in concert with next generation immunotherapy are also on the way to develop comprehensive measures to conquer this lethal disease. In this Special Issue, we would like to invite cutting-edge research covering the broad areas of preventive and therapeutic oncology.

Guest Editors

Prof. Dr. Hirendra Nath Banerjee


Department of Natural, Pharmacy and Health Sciences, Elizabeth City State University Campus of the University of North Carolina, Elizabeth City, NC 27909, USA

Dr. Santanu Dasgupta

Department of Medicine, The University of Texas Health North East MD Anderson Cancer Center, 11937 US Hwy 271, Tyler, TX 75708, USA

Deadline for manuscript submissions

closed (30 June 2019)



Medicines

an Open Access Journal
by MDPI

Indexed in PubMed



mdpi.com/si/18905

Medicines

Editorial Office

MDPI, Grosspeteranlage 5

4052 Basel, Switzerland


Tel: +41 61 683 77 34

medicines@mdpi.com

mdpi.com/journal/

[medicines](https://mdpi.com/journal/medicines)





Medicines

an Open Access Journal
by MDPI

Indexed in PubMed



[mdpi.com/journal/
medicines](https://mdpi.com/journal/medicines)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Hiroshi Sakagami
Meikai University Research Institute of Odontology (M-RIO), 1-1
Keyakidai, Sakado, Saitama 350-0283, Japan

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within PubMed, PMC, CAPlus / SciFinder, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 45 days after submission; acceptance to publication is undertaken in 5.7 days (median values for papers published in this journal in the first half of 2025).